Skip to content
S8465Senate2021-2022 SessionSame asA8519

Make Biologic Substitution Permanent

Official title

“Makes permanent certain provisions of law relating to interchangeable biological products”

Sponsor Gustavo RiveraSD-33Affects Education
Status
Senate Floor Calendar
Impact
3/10
Low
Outcome
Companion signed

Bill progress

Signed via A8519

What's happening

This bill makes permanent the law allowing substitution of interchangeable biological products for prescribed products in New York.

Why it matters

  1. Ensures long-term patient access to more affordable alternatives. By making the substitution of interchangeable biological products permanent, patients may see increased access to lower-cost biologic medicines, potentially reducing out-of-pocket costs for expensive treatments.

  2. Provides certainty for pharmacists and healthcare providers. Permanency means providers and pharmacists no longer need to worry about the law expiring, enabling them to plan and integrate biosimilar substitution into their long-term practices with confidence.

  3. Supports ongoing market competition. Keeping the law permanent encourages pharmaceutical manufacturers to develop biosimilars, fostering competition that can drive down prices on high-cost biologic drugs for the healthcare system overall.

  4. Aligns New York with national trends. As more states and federal guidelines support biosimilar substitution, this move positions New York to match broader efforts to increase access to safe, effective, and cost-saving medications.

The daily · weekday mornings

Albany, before your first meeting.

Every bill that moved yesterday, summarized in a sentence and ranked by impact. The Albany Scorecard follows on Sundays.

Free. Unsubscribe in one click. Want alerts on specific bills? Create an account.

Headline styles

Make Biologic Substitution Permanent

Plain English, a few words. Used as the page title.

Sponsors

Primary sponsor
Gustavo Rivera

Senator · Senate District 33

Chair, Health

No co-sponsors yet.

History

  1. Substituted by A8519
  2. Advanced to third reading
  3. 2nd report cal.
  4. 1st report cal.1245
  5. Referred to higher education

Companion bill

The same bill in the other chamber. A bill becomes law when one version passes both houses and the governor signs it, so either number can carry it.

A8519Assembly

Make Generic Biologics Permanent

Signed by Governor · Sponsor Richard Gottfried

Impact 3 · LowSigned into law

Full text

1 pageUnderlined is new[Struck] is removedOfficial text on nysenate.gov ↗

STATE OF NEW YORK

8465

IN SENATE

March 3, 2022

Introduced by Sen. RIVERA -- read twice and ordered printed, and when printed to be committed to the Committee on Higher Education

AN ACT to amend chapter 357 of the laws of 2017 amending the education law and the public health law relating to the substitution of interchangeable biological products for prescribed products, in relation to making such provisions permanent

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. Section 5 of chapter 357 of the laws of 2017, amending the education law and the public health law relating to the substitution of interchangeable biological products for prescribed products, is amended to read as follows:

§ 5. This act shall take effect immediately [and shall expire five years after having become a law].

§ 2. This act shall take effect immediately.

EXPLANATION--Matter in italics (underscored) is new; matter in brackets

[ ] is old law to be omitted.

LBD13636-01-1

Reflowed for reading: line numbers and page breaks removed. Cite the official text.

Sponsor's memo

Title of bill

An act to amend chapter 357 of the laws of 2017 amending the education law and the public health law relating to the substitution of inter- changeable biological products for prescribed products, in relation to making such provisions permanent

Purpose or general idea of bill

To make permanent existing law that allows pharmacists to substitute biosimilar medications under certain conditions.

Summary of specific provisions

The bill amends the enacting date of the original statute to strike the sunset of that law.

Justification

Biologic therapies have revolutionized the treatment of complex chronic diseases such as cancer, heart disease, arthritis, multiple sclerosis, HIV/AIDS, among others. There are currently more than 200 FDA approved biologic medications. Like the generic drugs that pharmacists may substitute for their branded counterparts, the federal Food and Drug Administration approves biologic medications that are interchangeable, referred to as "biosimilars". Because the interchangeable biosimilar is not an identical molecule as is the case with generic drugs, a separate law was required to authorize the substitution.

The current New York law permitting substitution with FDA-approved bios- imilar products is similar to the law authorizing substitution of gener- ic drugs for brand-name drugs.

The biosimilar law will sunset in October 2022. This bill would make the existing law permanent. This bill will ensure that patients with diffi- cult to treat and rare conditions will continue to benefit from the availability of biologic medications that are designated as interchange- able by the FDA.

Prior legislative history

New bill.

Fiscal implications

None.

Effective date

Immediately.

Summaries, headlines and scores are AI-generated from the official bill text. How we score bills. Source: NYS Open Legislation.